Gefitinib

Lung Cancer

Fuzhou General HospitalSmall moleculePhase 3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 68/ 100
Competitive Position: 65/ 100

Competitive context

298 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont	Phase 4	BB
Carboplatin SystImmune Inc.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Gefitinib is also rated in:

central nervous system neoplasmDormant

BBB

Indicative · Phase 2

73 / 100

gliosarcomaDormant

BB

Indicative · Phase 2

71 / 100

lung large cell carcinomaDormant

BB

Indicative · Phase 3

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.